Dr. David A. Dulitz, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in New Orleans (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 90
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: Louisiana State University School of Medicine in New Orleans
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
LA license 11984R
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Leonard J Chabert Medical Center Houma, LA
Medical groups
- South Louisiana Medical Associates (113 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 90
- Services billed
- 211
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 150 | 81 |
| New patient office or other outpatient visit, 45-59 minutes | 36 | 36 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 24 | 23 |
| Diagnostic exam of large bowel using a flexible endoscope | 13 | 12 |
| Biopsy of large bowel using a flexible endoscope | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in Luling, LA | 241 |
| Dicyclomine Hcl Other prescribers in Luling, LA | 69 |
| Omeprazole Other prescribers in Luling, LA | 66 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Luling, LA | 62 |
| Esomeprazole Magnesium Other prescribers in Luling, LA | 38 |
| Clenpiq (sod picosulf/mag ox/citric ac) | 26 |
| Movantik (naloxegol oxalate) Other prescribers in Luling, LA | 22 |
| Mesalamine Er (mesalamine) Other prescribers in Luling, LA | 17 |
| Linzess (linaclotide) Other prescribers in Luling, LA | 17 |
| Humira(Cf) (adalimumab) Other prescribers in Luling, LA | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 10 payments worth $212 in total to this clinician.
| Genzyme Corporation | $58.66 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $56.93 |
| AbbVie Inc. | $44.41 |
| Novo Nordisk Inc | $35.69 |
| Phathom Pharmaceuticals, Inc. | $16.71 |
| Food and Beverage | $212 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $1,491,393 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis.
Celgene Corporation - A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Eli Lilly and Company · Active, not recruiting · NCT06598943 - A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis.
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.